

# INDEX

- ABI microarrays, 63  
A cells (migratory neuroblasts), 39  
Actin-binding proteins, 214  
Activin A, long-term expression of, 98  
Activity-based protein profiling (ABPP), 150  
Acute myeloid leukemia (AML), 49–51  
Address oligonucleotides, 63  
Adenomatous polyposis coli (APC) homologs, 31  
Adenomatous polyposis coli tumor suppressor gene, 48  
Adenoviral vectors, 96, 98  
Adherent growth, 9  
Adult neurogenesis, 39  
Adult rodent NSCs, gene trap in, 199  
Adult stem cell biology, 52–53  
Adult stem cell lineages, 33  
Adult stem cell niche, 30  
    identifying, 32–33  
Adult stem cells, 4, 27–58, 171, 188  
    fundamental properties of, 28  
    genomic mutations of, 47  
    properties of, 52  
    regulation and dysregulation of, 29  
Adult stem cell technology, innovation in, 42  
Affinity chromatography, 198  
Affinity enrichment systems, 158  
Affinity labeling, 131–134  
Affinity matrix, 133  
Affinity purification, 131  
Affinity reagents, 157  
Affymetrix, 63, 64, 70, 75  
Affymetrix dataset, 65  
Agilent, 63  
Allelic variability, 177  
Alopecia, 44–45  
 $\alpha$ -tubulin hyperacetylation, 122  
Alternative mRNA splicing, 75  
Alzheimer's disease (AD), 40  
Ambion, 74  
Amino acids, stable isotope labeling with, 234–235  
Amphibian limb, regenerating, 208  
Amphibians, in regeneration studies, 210  
Amplification technologies, 65  
Amplified antisense RNA (cRNA), 60  
Analysis of variance (ANOVA), 67  
Analytical tools, 171–174  
Anticancer compounds, screens for, 73  
Anuran amphibians, in regeneration studies, 210  
API signaling pathway, functional profiling of, 89  
APC/ $\beta$ -catenin destruction complex, 48  
Apical ectodermal ridge (AER), 212  
Apoptosis, TRAIL-induced, 92–93

- Apratoxin A, 136  
 ARF-GAP functions, 197  
 Array-based SNP technologies, 74  
 Array comparative genomic hybridization (aCGH), 75  
 Array Express, 71  
 Array image capture, 67  
 Arrays, spotted and synthesized, 60  
 Artificial cell immortalization, 182  
 Assay conditions, permissive, 191  
 Assays, long- versus short-term, 95  
 Astrocyte stem population, 40  
 Astroglial differentiation, 194  
 Asymmetric division, 28, 193  
 ATCC clone library, 85  
 ATP-binding cassette (ABC) transporter family, 52  
 Autologous skin transplants, graftable matrices for, 44  
 Automated microscopy, 90  
 Automated synthesis, enabling technologies for, 111  
 Axonal regeneration, 195  
 5-Aza-C DNA demethylation agent, 194  
 Azide-containing analogs, 158
- Baldness, 44–45  
 Barluenga, Sofia, vii, 109  
 Basic helix-loop-helix (bHLH) factors, 7  
 Basic helix-loop-helix leucine zipper (bHLHLZ) protein family, 125  
 B cells (SVZ astrocytes), 39  
   hematopoietic-lineage, 34  
 Bcr-Abl-kinase inhibitors, 117–118  
 Benzodiazepines, 112  
 Benzopyran library, synthesis of, 119  
 Benzopyran motif, 118  
 $\beta$ -catenin destruction complex, 48  
 $\beta$ -catenin interactors, 230  
 $\beta$ -catenin phosphorylation, 237  
 $\beta$  cells, insulin-producing, 16  
 $\beta$ geo cassette, 14  
 bFGF (basic fibroblast growth factor), 8, 9  
 Bioavailability, predicting, 112  
 Bioconductor project, 66  
 Bioinformatic algorithms, development of, 181–182  
 Biologically active molecules, libraries of, 113  
 Biological mass spectrometry, protein characterization by, 145–167  
 Biology, probing with small molecules, 109–144  
 Biomolecule-compatible ionization techniques, 145  
 Biotin-streptavidin biochemical affinity pair, 158  
 Blastema, 208  
   cells of, 212  
   Blastomeres, 1–2  
   Blood–brain barrier, 41  
   BMP receptor (BMP<sub>r</sub>) mutants, 47  
   Bone-forming osteoblasts, 36  
   Bone marrow, HSC homeostasis and, 29  
   Bone marrow transplantation, 27, 28, 34  
     workings of, 36–37  
   Bone morphogenetic protein (BMP), 36, 47, 191, 192. *See also* Serum/BMP  
   Bone morphogenetic protein-4 (BMP<sub>4</sub>), 6–7, 8, 200. *See also* BMP receptor (BMP<sub>r</sub>) mutants  
   Bone morphogenetic protein-9 (BMP<sub>9</sub>), 90  
   Bottom-up approach, 227  
   Bottom-up proteomics, 147, 159  
   BrdU DNA base analog, 39  
   6-Bromindirubin-3'-oxime (BIO), 192  
   Bulge activation hypothesis, 43  
   Bulge cells, 43
- C2C12 myoblasts, 196  
 C57B1/6 embryos, 3–4  
 Cadherin–catenin interface, 36  
 cAMP (cyclic AMP), in osteogenesis versus adipogenesis, 201  
 Cancer. *See also* Tumor entries  
   gastrointestinal tract, 48  
   initiation of, 188  
   therapeutic treatments for, 37  
 Cancer induction, developmental pathways and, 197  
 Cancer models, 50  
 Cancer stem cell model, 51  
 Cancer stem cell pathways, targeted treatment of, 52  
 Cancer stem cells, 47, 49–52, 188–189  
   relationship to tissue-specific stem cell populations, 179  
   therapeutic considerations related to, 51–52  
 Cancer stem cell theories, 51  
 Candidate gene approaches, 209, 219  
   to regeneration, 211–212  
 Cap cells, 32  
 Capillary electrophoresis, 147  
 Carbohydrate microarrays, 128  
 Carbohydrate sulfotransferase inhibitors, 117  
 Cardiomyocytes, 12  
   proliferation of, 195  
 $\beta$ -Catenin interactors, 230  
 $\beta$ -Catenin phosphorylation, 237  
 C cells (progenitor or transit-amplifying), 39  
 CD59 pathway, 214  
 Cdc25A protein phosphatase, 125, 126  
 Cdc42-dependent functions, 122

- CDK1 (cyclin-dependent kinase-1), 93  
   inhibition of, 132–133  
 CDK-related kinases (CRKs), 134  
 cDNA clone collections/libraries, 60, 199. *See also*  
   cDNA libraries  
 cDNA clones, 85  
 cDNA libraries  
   biased, 88–89  
   development of, 198  
 cDNAs (complementary DNAs)  
   overexpressed, 88–90, 97  
   profiling the effects of, 90  
   synthesis of, 65  
 Cell assays, engineering, 191  
 Cell-autonomous regeneration paradigms, 219  
 Cell-based therapies, 188  
 Cell culture, inconsistency in, 190  
 Cell-cycle-inhibiting proteins, 51  
 Cell cycle progression, regulating, 93  
 Cell-cycle-promoting proteins, 51  
 Cell immortalization, 182  
 Cell lines, defining relatedness of, 181  
 Cell plasticity, 196  
 Cell replacement therapies, 188  
   for neurodegenerative diseases, 13–14  
 Cells  
   compiling combined information  
     on, 181–182  
   growing in isotopically enriched media, 152  
 Cell surface marker proteins, 42  
 Cell surface markers, 37, 39, 49, 74  
 Cell survival signaling, 193  
 Cell typing, use of miRNA profiling in, 180  
 Cellular gene function, exploring via genomic  
   functional profiling, 86–93  
 Cellular reprogramming, 195–196  
 CENTA1 protein, 86  
 Central nervous system (CNS), tissue damage  
   to, 38  
 Centre for Modeling Human Disease, 199  
 Centrosomin, 32  
 Chemical-based affinity systems, 158  
 Chemical epistasis studies, 194  
 Chemical isotope-tagging strategies, 230  
 Chemical labeling, quantitation using, 155  
 Chemical libraries  
   designing better, 201  
   privileged, 190  
   qualities of, 190  
 Chemical modulators, of developmental  
   pathways, 197  
 Chemical screens, 219  
   for small molecules that affect regeneration,  
   217–218  
 Chemical space, 112, 113  
 Chemical tags, in encoding methods, 110–112  
 Chemical technologies, 109–144  
 Chemoselective ligations, 158  
 Chemoselective reactions, 127–128  
 Chemotherapeutic agents, enhancers of, 93  
 Chesnut, Jonathan D., vii, 169  
 Chimeric hair follicles, 43  
 ChIP on chip approaches, 75  
 Cholesterol metabolism, 118  
 Chromatin immunoprecipitation, 64  
 Chromatographic methods, 151  
 Clark, Julie, vii, 187  
 Clustering algorithms, 68  
 CodeLink, 63  
 Colchicine, 131  
 Collision-induced dissociation (CID), 225  
 Colony-forming cells, 49  
   hematopoietic, 15  
 Colony hybridization technique, 60  
 Columnar cells, 46  
 CombiMatrix, 64  
 Combinatorial libraries, 112  
   synthesis of, 116  
 Combinatorial networks, of posttranslational  
   modifications, 156  
 Combinatorial synthesis, 110–112  
 Comgenex, 113  
 Commercial microarrays, 74  
   vendors of, 63–64  
 Comparative analysis, 228  
 Comparative database-searching  
   techniques, 146  
 Complementary DNAs. *See* cDNA entries  
 Computation analysis, 180  
 Conditioned media, identification of secreted  
   proteins in, 229  
 Correlation ( $R^2$  score), among NSC, APC, and  
   OPC samples, 176  
 Cowan, Chad A., vii, 27  
 CREB signaling, functional profiling of, 89  
 Cross-species comparisons, 17  
 Crypt-base columnar cells, 46  
 C-terminal carboxylic acid functionalities, 152  
 C-terminal labeling, 230  
 Cultured cells, small-molecule screens conducted  
   on, 218  
 CYLD protease, 91  
 CYP7A1 regulation, 118  
 Cyst progenitor cells, 31–32  
 Cytoblot assay, cell-based, 122  
 Cytokeratin-15 (K15), 44  
 Cytokines, 7  
 Cytokine signaling suppressors, 11

- Cytotoxic compounds, 135  
 activity of, 137  
 novel, 136
- Data clustering, 68
- Data-dependent analysis schemes, 147, 149
- Data-mining algorithms, development of, 181–182
- Data repositories, for stem cell microarray experiments, 71
- Datasets, comparing, 174, 175–176
- “Data warehouses,” 70–71
- D cells, 40
- Dedifferentiation process, 208
- Developmental pathways, modulators of, 196–197
- Developmental processes, high-throughput small-molecule screens for, 218
- Dexamethasone, 194
- Differential colony hybridization, 60
- Differential gene expression technology, 61–62
- Differentially expressed genes, screens for, 212–215, 219
- Differentiation  
 lineage-specific, 193–194  
 Msx genes in the inhibition of, 212  
 regulation of, 31–32
- Differentiation assays, 99
- Differentiation promoting factors, 219
- Ding, Sheng, vii, 187
- 1,3-Dioxane library, 118–121  
 synthesis and microarraying of, 120
- Diseases, stem cells in treating, 187
- Diverse molecules, synthesis of libraries consisting of, 113–114
- Diversity, measuring and designing, 112–113
- Diversity-building reaction, 113–115
- Diversity generation, reactions with high potential for, 114
- Diversity-oriented synthesis, 115, 122
- Diversity space, 112
- DNA copy number, tracking changes in, 75
- DNA demethylation agents, 194, 197
- DNA microarrays, widespread adoption of, 85
- DNA sequencing technologies, 60
- Dominant neutral loss, during tandem MS, 159
- Dopaminergic neurons, 12, 13
- Drosophila*, niche location and identification in, 32
- Drosophila* GSC niche, 31–32
- Drug approval process, 69
- Drug discovery, lead compound optimization in, 73
- Duchenne muscular dystrophy (DMD), 214
- Dystrophin, 214
- Early gene functionalization, in mammalian cells, 84–86
- Eberwine amplification scheme, 65
- Ectoderm, generation of, 12–14
- Ectopic gene-expression screen, 217
- Electron-capture detection (ECD), 159
- Electron-capture dissociation (ECD), 227
- Electron transfer disassociation (ETD), 159–160
- Electrospray ionization (ESI), 145, 225–226
- elg-19* gene, 136
- Elledge–Hannon library, 92
- Embryoid bodies (EBs), 9, 12
- Embryonic carcinoma (EC) cells, 1, 2, 3
- Embryonic germ (EG) cells, 1, 2
- Embryonic stem (ES) cells (ESCs), 1–25, 171, 178–179, 188. *See also* ESC entries; ES cell entries; Human embryonic stem cells (hESCs); Murine embryonic stem cells (mESCs)  
 derivation of, 3–4  
 key properties of, 4  
 origin of, 1–3  
 miRNAs in, 180  
 as target populations for proteomic interrogation, 228
- Embryos, Oct4 deficient, 9
- Encoded libraries, 92
- Encoding methods, chemical tags in, 110–112
- Endoderm derivatives, generation of, 15–16
- “Enhancing” mutations, 217
- Enteroendocrine cells, 46
- Entrez Gene database, 84
- Enzymatic isotope labeling techniques, 230
- Enzyme profiling, 128
- EphB2 cell surface target, 72
- Epiblast cells, 2–3
- Epicentre, 65
- Epidermal growth factor (EGF), 235
- Epigenetic changes, tools for systematic analysis of, 180
- Epigenetic modifiers, 196–197
- Epigenetic profiles, for distinguishing stem cells, 180–181
- Epithelial cells, 42
- Epithelial stem cell niche, 43–44
- Epithelial stem cells, 41–45  
 as barriers, 48  
 functions of, 45  
 identification of, 42–43  
 skin and intestinal, 41–42  
 therapeutic considerations related to, 44–45
- Epithelial-to-mesenchymal transition (EMT), 195
- Epithelium, 41–42

- EPO/EPOR binding, 125
- Eras-null mouse ES cells, 9
- Erg2p target, 136
- Erk1 protein, 192
- Erlotinib, 195
- ESC clones, 199
- ES cell-derived hematopoietic progenitors, 15
- ES “cell fate” decision, 5
- ES cell fate determination
- extrinsic factors in, 8–9
  - intrinsic determinants of, 9–11
- ES cell identity, establishment of, 11
- ES cells, 3. *See also* Embryonic stem (ES) cells (ESCs)
- differentiation of, 12–16
  - Nanog-null, 10
  - potential applications of, 16–17
  - species differences in, 176
- ES cell self-renewal, 192
- maintenance of, 5–12
  - negative regulators of, 11–12
- ESC-specific proteins, 228
- ES-like cells, 1
- ES-specific genes, 174
- N*-Ethyl-*N*-nitrosourea (ENU) mutagenesis screen, 215, 216
- Ethyl-*N*-nitrosourea (ENU) mutagenesis studies, 71
- Exiqon, 74
- Exogenously applied growth factor screens, 217
- Expressed sequence tags (ESTs), 85
- Expression profiling, 86
- using microarrays, 72
- External RNA Controls Consortium (ERCC), 69
- Extracellular regulated kinases (ERK), 6
- Extracellular-signal-related kinase (ERK), 191–192
- Extrusion zone, 45
- Ex vivo* stem cell culturing, 44
- “False discovery rate,” 67
- False positives/negatives, 94
- Familial adenomatous polyposis (FAP), 48
- Farnesoid X receptors (FXR), 118
- Feature comparison techniques, 151
- Feeder cell layers, as a source for stem cell regulators, 229
- Feeder cells, 3
- Feeder-independent cells, 8
- Fenno, Lief, vii, 27
- Fetal neural stem cell (NSC) survival, 193
- Fexaramine, 118
- Fexaramine-induced FXR activation, 118
- FGF8 (fibroblast growth factor 8), 13
- FGFRs (fibroblast growth factor receptors), 136
- 53BP1 pathway, 91
- Fission process, 46
- 5-aza-C DNA demethylation agent, 194
- FK506 immunosuppressant drug, 133, 218
- 5-Fluorouracil (5FU), 134, 135
- Fluorescent dye, in sample-labeling techniques, 64–65
- Fluorescent markers, 98–99
- Fluorocarbon tags, 110
- Fluorous derivatization and enrichment methodology, 158
- Focused libraries, 113
- Focused screens, 214
- Forkhead transcription factor, 11
- Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, 226
- FoxD3 transcription factor, in ES cell fate determination, 10–11
- FOXO1 translocation, 90
- Full-transcriptome exon array, 75
- Fumagillin, 131
- Functional genomic profiling experiments, weighing factors in, 95–96
- Functional genomics approaches, to stem cell research, 198–200
- Functional genomic screens, viral delivery methods for, 200
- Functional profiling, overexpression-based, 88–90
- Functional profiling assays, 88
- Functional profiling strategies, considerations when applying, 93–96
- Functional screens, 215
- G1/S progression, 93
- G2/M progression, 93
- Gain-of-function screens, 200
- Galanthamine, 122
- Galanthamine-inspired library, synthesis of, 124
- Gastrointestinal cancers, 48–49
- Gata4 factor, 11–12
- Gata6 factor, 11–12
- Gata factors, ES cell self-renewal and, 11–12
- Gene expression, miRNA and, 180
- Gene expression analysis, 198
- analytical tools for, 180
- Gene expression data, steps in analyzing, 66
- Gene expression datasets, public, 70–72
- Gene expression microarrays, 59
- therapeutic targets and, 72
- Gene expression microarray technology, application of, 72

- Gene Expression Omnibus, 71
- Gene expression pattern, 175
- Gene expression profile database, 136
- Gene expression profiles, 17, 85–86  
comparing, 213
- Gene function, modulation of, 188
- Gene Ontology (GO) project, 68
- Gene product interaction databases, 68
- Gene products, unclassifiable, 85
- Genes  
approaches to studying, 145  
Ure2p-dependent, 121
- Genetic regeneration enhancers, screens for, 216–217
- Genetic screens, for regeneration prevention  
mutations, 215–216
- Gene transfer, 182
- Gene trap, 198–199
- Gene trap cassette, 199
- Genewise queries, 71
- Genisphere, 65
- Genome-scale analysis, 99
- Genome-scale shRNA RNAi libraries, 96
- Genome-scale siRNA libraries, 93
- Genome sequences, 223  
availability of, 85
- Genomewide expression analysis technologies, 59–81
- Genomewide expression profiling, 194
- Genomic analysis, 17  
methods for, 171–174
- Genomic datasets, use in the drug approval  
process, 69
- Genomic functional profiling, 83–107  
advantages of, 86  
application to stem cell biology, 97–99  
exploring cellular gene function via, 86–93  
using RNA interference libraries, 90–93
- Genomic functional profiling experiments,  
methodology of, 87–88
- Genomic functional profiling technology, recent  
developments in, 97–98
- Genomic overexpression screen, 136
- Genomics revolution, 85
- Germline stem cells (GSCs), 29  
in *Drosophila*, 31–32
- Glial fibrillary acidic protein (GFAP), 39, 40
- Glia precursors, 12
- Global gene expression, comparing, 173–174
- Global gene expression analysis, 73
- Global gene expression profiling, 59
- Global methylation studies, 181
- Global pairwise comparisons, 177
- Global proteomic interrogation, stem cell  
properties warranting, 224
- Global proteomics, 228
- Glucagon-like peptide 2 (Glp2), 47
- Glycopeptides, 236
- Glycoprotein capture technology, 236–237
- N*-Glycosylated protein isolation technologies,  
236–237
- “Gly-Gly” tag, 158
- Goblet cells, 46
- gp130-LIFR (LIF receptor) complex, 191
- Graftable matrices, 44
- Graft-versus-host disease (GVHD), 37
- Granule cells, 40
- Granulocyte macrophage colony stimulating factor  
(GM-CSF), 14
- Green fluorescent reporter gene (GFP), 36
- GRK4 (G protein-coupled receptor kinase 4), 95
- Growth factor screens, 217
- $H_3PO_4$  loss, 159
- Hair follicles, 43
- Haploinsufficiency, 134
- HDAC inhibitors, 197
- Heatmaps, 68
- Hedgehog signaling pathway, 198
- HEK293T cells, 88–90
- HeLa cells, 92, 93
- Hematopoietic differentiation (mesoderm),  
14–15
- Hematopoietic lineages, 14
- Hematopoietic progenitor cell lines,  
multipotent, 233
- Hematopoietic progenitors, ES cell-derived, 15
- Hematopoietic stem cell niche, 29–30, 36–37
- Hematopoietic stem cells (HSCs), 27, 34–38. *See also* HSC entries  
benefits of, 37–38  
discovery of, 35  
dysregulation of, 29  
human, 36  
identification of, 34–36  
lifespan of, 193  
molecular signature of, 234  
purified, 38  
therapeutic applications of, 37
- Hematopoietic system, reconstituting, 37
- Heritable epigenetic remodeling, 180–181
- Heterocycle library, 191
- Hexokinase (HK), 95
- Hh pathway antagonists, 194
- HIF1A (hypoxia inducible factor), 95
- High-content phenotypic assays, 137

- High-throughput functional genomic screens, 198, 199–200
- High-throughput functional screens, large-scale, 200
- High-throughput screening (HTS), 94, 112, 137
- High-throughput small-molecule screens, 218
- High-throughput technologies, 83
- Hilcove, Simon, vii, 187
- Hippocampal neural progenitor cells, differentiation of, 193–194
- His-3 reporter gene, 133, 134
- Histocompatibility profiles, 173
- Histone deacetylases (HDAC), inhibitors of, 121–122
- Histone hyperacetylation, 122
- Homozygous mutant cells, genomewide library of, 199
- hphkt* gene, 14
- HSC-activating factors, 36. *See also* Hematopoietic stem cells (HSCs)
- HSC transplantation, 37
- HSP90 chaperone, 131
- Human accelerated region (HAR) RNAs, 91
- Human adult neural precursor, 39
- Human embryonic stem cells (hESCs), 170, 173, 229
- Human ES cell fate determination, extrinsic factors in, 8–9
- Human genes, PubMed citations per, 84–85
- Human Genome Project, 224
- Human MSCs (hMSCs), osteogenesis and adipogenesis screens in, 200–201. *See also* Mesenchymal stem cells (MSCs)
- Human umbilical vein endothelial (HUVEC) cells, 90
- Hybrid linear ion trap-triple quadrupole (QTrap™) mass spectrometers, 158
- Hydrazine-containing reagents, 157
- Hydrogen-tritium substitution, 131
- Hypothesis-driven multistage MS, 159
- ICAT-MS/MS method, 233
- Identity, measures of, 173
- IL6 family, 6
- Illumina, 63, 64, 65, 70, 181
- Illumina arrays, 74
- Immobilized metal affinity chromatography (IMAC), 157, 158
- Immortality-associated genes, 178, 179
- Immortal strand theory, 47–48
- Immunopurification, MS/MS coupled with, 229–230
- Immunoreceptor tyrosine-based motifs (ITAM), 237
- Immunosuppressants, 37
- Indoloquinolizidines, 126
- Information, compiling, 181–182
- Information tracking, for microarray experiments, 66–67
- Inhibitors, in mouse ES cell fate determination, 7–8
- Inner cell mass (ICM), 1, 2
- In situ* screening, library for, 112
- “Instructive” genes, 215–216
- Insulin-producing  $\beta$  cells, 16
- Insulin-producing pancreatic cells (endoderm), 15–16
- Integrative viral vectors, 98
- Intestinal crypts, 47–48
- Intestinal stem cell niche, 46–47
- Intestinal stem cell proliferation, regulation of, 47
- Intestinal stem cells, 45–49
  - identification of, 46
  - molecular markers of, 49
  - self-renewal of, 230
  - therapeutic considerations related to, 48
- Intestinal villi, 45
- Intrareplicate expression level, 68
- “Inverse labeling” methodologies, 152
- Invitrogen, 74
- In vitro*-generated cells, 12
- Ionizing radiation, exposure to, 27
- Ischemia, 41
- Islet-like structures, derivation of, 15–16
- Isobaric tagging for relative and absolute quantitation (iTRAQ), 233–234
- Isoindoline library, 125
- Isotope-coded affinity tag reagents, 232–233
- Isotope coded affinity tags (ICATs), 153, 229
- Isotope-coded affinity tag technology, 230
- Isotopically enriched media, growing cells in, 152
- Isotopic labeling/tagging, 151–152, 156. *See also* Label entries
  - quantitation using, 154
  - strategies for, 230, 232–235
- ITMS (ion trap mass spectrometry), 226
- iTRAQ (isobaric tag for relative and absolute quantitation) methodology, 153
- iTRAQ reagents, 155
- JAK-STAT signal transduction pathway, 31
- Keratinocytes, 42
- Ketone-containing analog, 158
- Key genes, testing the contribution of, 99
- Kinase inhibition, 133
- Kinase profiling, 128, 130
- Kinases, structure-based libraries targeting, 115–118

- Knockout embryos, FoxD3, 11  
*Kyoto Encyclopedia of Genes and Genomes* (KEGG), 68
- “Label-free” quantitation schemes, 151
- Labeling technologies, microarray, 64–65. *See also* Isotopic labeling
- Label-retaining cells (LRCs), 48
- Label-retaining phagosomes, 46
- Label-retaining techniques, 42
- Laboratory information management system (LIMS), 67
- Large-scale functional genomic screens, 209–210, 212–218
- Large-scale genetic approaches, 200–201
- Large-scale genomic analysis  
of stem cell populations, 169–186  
workflow stages of, 172
- Larva-stage, large-scale regeneration screen, 218
- LC-MS analysis, 121. *See also* Liquid chromatography (LC)
- LC/MS/MS (liquid chromatography tandem mass spectrometry)  
analysis of peptide mixtures by, 148  
in phosphopeptide-capturing technology, 237
- LC-MS/MS-based proteomic technologies, 229–230
- LC/MS/MS methodologies, multidimensional, 150
- Lead compound optimization, 73
- Lectin affinity capture technology, 236
- Lectins, 157
- Lentiviral shRNA library, 92
- Lentiviral vectors, 96, 98
- Leukemia inhibitory factor (LIF), in mouse ES cell fate determination, 5–6. *See also* LIF entries
- Libraries  
combinatorial, 112  
inhibitor-yielding, 115–127
- LIF/interleukin-6 (IL6) family, 191. *See also* Leukemia inhibitory factor (LIF)
- LIF signaling, 176
- LIF/Stat3 pathway, 8
- LIF/Stat3 target gene(s), 6. *See also* Stat3 (signal transducer and activator of transcription 3)
- Ligand–protein interaction, 128
- Lineage-committed cells, reprogramming, 196
- Lineage minus (lin minus), 34
- Lineage selection strategy, 13–14
- Lineage-specific differentiation, 193–194
- Linear ion trap (LIT) analyzers, 226
- Linear (two-dimensional) ion traps, 149
- Lipid-based transfection, 96
- Lipid-mediated transfection, 97
- Lipinski’s rule-of-five, 112–113
- Liquid chromatography (LC), 226. *See also* LC entries; MALDI-LC/MS/MS analysis platforms
- LIT-FTICR (linear ion trap–Fourier transform ion cyclotron resonance), 226. *See also* Linear (two-dimensional) ion traps
- Liver X receptors (LXR), 118
- Long-term assays, 95
- Long-term reconstituting hematopoietic stem cells (LSK<sup>+</sup>), 234
- LTQ FTICR mass spectrometer, 150
- Major histocompatibility (MHC) immunomatching, 37
- MALDI-LC/MS/MS analysis platforms, 147–149. *See also* Liquid chromatography (LC); Mass spectrometry (MS); Matrix-assisted laser desorption/ionization (MALDI)
- MALDI-MS, 226
- MALDI MS/MS, 236
- Mammalian cell lines, use in a resistance screen, 136
- Mammalian cells  
early gene functionalization in, 84–86  
regenerative capacity of, 195
- Mammalian Genome Consortium, 85
- Mammalian models, in regeneration studies, 211
- Mammals, immortal strand hypothesis and, 47–48
- MAPK pathway, 90. *See also* Mitogen-activated protein kinases (MAPK)
- Marelli, Anthony, vii, 83
- Marked stem cells, discriminating, 98
- MASCOT<sup>TM</sup>, 147
- Mass spectrometry (MS), 145–146. *See also* MALDI entries; MS entries; Protein MS characterizing posttranslational modifications by, 156–160  
protein identification using, 146–150  
protein quantitation using, 150–156  
in proteomic research, 224–230  
use in measuring changes in peptide levels, 151
- Mass-to-charge ratio (*m/z*), 226
- Matrix-assisted laser desorption/ionization (MALDI), 145, 225–226. *See also* MALDI entries
- mdx* mice, in regeneration studies, 214
- Medina, Myleen, viii, 83
- Mesenchymal cells, BMP-secreting, 47
- Mesenchymal stem cells (MSCs). *See also* Human MSCs (hMSCs); Mesenchymal stem/progenitor cells  
differentiation of, 235  
osteogenesis of, 194

- Mesenchymal stem/progenitor cells, differentiation of, 194
- Mesoderm lineages, 14–15
- Messenger RNAs (mRNAs). *See also* mRNA entries
- cdNA synthesis from, 65
  - detectability with microarrays, 70
  - Gata4, 11
- Metabolic interconversion, 158
- MetAP2 metalloprotease, 131
- Methodrexate (MTX), 133–134
- Methylation analysis, 74
- Microarray analysis, components of, 69
- Microarray analysis methods, maturation of, 69–70
- Microarray analysis tools, 65–69
- Microarray core facilities, 64
- Microarray data, extraction, analysis, and mining of, 60
- Microarray designs, improvements in, 70
- Microarray detection methods, 200
- Microarray experiments
- expense of, 70
  - reproducibility of, 69
  - software options for, 66
  - testing errors in, 67
- Microarray gene expression comparison, 213
- Microarray Gene Expression Data (MGED) Society, 69
- Microarray profiling, 73
- Microarray Quality Controls Consortium (MAQC), 69
- Microarrays
- applications of, 72–74
  - expression profiling using, 72
  - global gene expression profiling using, 59
  - history of, 59–62
  - sample amplification and labeling, 64–65
  - stem cell information from, 73–74
- Microarray service providers, 64. *See also* Microarray vendors
- Microarray technologies, 127–128
- automation of, 70
  - evolving, 75
  - new and complementary, 74–75
- Microarray vendors, 64
- commercial, 63–64
- MicroRNA noncoding RNAs, 92
- MicroRNAs, 74
- Microtubule destabilization, 117
- Minimal information about a microarray experiment (MIAME), 174
- Minimum expression threshold, 68
- miRNA, target genes regulated by, 180
- miRNA profiling, use in cell typing, 180
- Mitogen-activated extracellular signal regulated kinase (MEK1), 196
- Mitogen-activated protein kinases (MAPK), 6
- Mitotic spindle, 31
- Model organisms
- regeneration screens in, 207–222
  - for regeneration studies, 210–211
- Modifiers, epigenetic, 196–197
- Molecular diversity, 114
- Molecular regeneration enhancers, screens for, 216–217
- Molecular studies
- approaches to, 209–210
  - of regeneration, 211
- Molsidomine, 134
- Monitoring-initiated detection and sequencing (MIDAS), 159
- Monolayer differentiation, 12
- Morpholino antisense technology, 216
- Motor neurons, generation of, 194
- Mouse embryonic fibroblasts (MEFs), 3, 229
- as feeder layers, 8
- Mouse embryonic stem cell clones, gene-trap-mutated, 199. *See also* Murine embryonic stem cells (mESCs)
- Mouse ES cell fate determination, extrinsic factors in, 5–8
- Mouse Gene Prediction Database, The, 71
- Mouse genome, diploid nature of, 199. *See also* Null mice; Severe combined immunodeficient (SCID) mice
- MptpA protein phosphatase, 125, 126
- MptpB phosphatase inhibitor, 127
- MptpB protein phosphatase, 125, 126
- MRL mouse strain, 216–217
- mRNA-level differences, measuring, 67. *See also* Messenger RNAs (mRNAs)
- mRNA levels, 233
- measurement of, 74
  - number of genes expressed by, 181
- mRNA sequences, unhybridized, 60
- mRNA splicing, 75
- MS<sup>3</sup> (MS/MS/MS) strategies, 159. *See also* Mass spectrometry (MS); Tandem mass spectrometry (MS/MS)
- MS analyzers, 147
- MS-based protein biomarker discovery, 160
- MS-based proteomic strategies, 227
- MS-based studies, evaluating, 149–150
- MS scanning and fragmentation
- methodologies, 158
- msxB* expression, 212
- Msx genes, 211–212

- Multidimensional protein identification technology (MuDPIT), 149
- Multiple sclerosis (MS), genes expressed in, 72
- Multipotent adult stem cells, 28
- Multistage mass spectrometry, 226
- Murine embryonic stem cells (mESCs), 191, 194.  
*See also* Mouse embryonic entries  
long-term cultures of, 192
- Mushashi-1, 47
- Mutant alleles, 215
- Myc-Max dimerization, 125
- Myc signaling, 192
- Myelin, inhibitory activity of, 195
- Myoblasts, reprogramming, 196
- Myoseverin, 117, 195, 198, 218
- Myotube fission, 117
- Nanog, 83, 199  
in ES cell fate determination, 10  
long-term expression of, 98
- Natural-product-based libraries, 113
- Natural products, total synthesis of, 113
- N-CoR nuclear corepressor, phosphorylation status of, 99
- ncRNAs, 91–92
- Neomycin B library, 115
- Neural cells, embryonic stem cell-derived, 13–14
- Neural crest stem cells (NCSCs), 176
- Neural differentiation (ectoderm), 12–14, 193–194
- Neural precursors, 14, 39
- Neural stem cells (NSCs), 38–41, 170, 171, 177, 178–179. *See also* NSC entries  
biology of, 41  
identification of, 38–39  
potency of, 39  
therapeutic considerations related to, 40–41
- Neurodegenerative diseases, cell replacement therapies for, 13–14
- Neurogenesis, adult, 39
- Neuronal differentiation, 193–194
- Neurons  
generation of, 13  
regenerative incompetence of, 195
- Neuropathiazol, 193–194
- NF- $\kappa$ B activation, 91
- NIC-60 cancer cell line, 136
- Niche, 29–34  
adult stem cell, 32–33  
*drosophila* GSC, 31–32  
epithelial stem cell, 43–44  
hematopoietic stem cell, 36–37  
intestinal stem cell, 46–47  
molecular mechanisms of, 33–34  
regulation of proliferation in, 30  
regulation of stem cell fate in, 31–32
- Nimblegen, 63, 64
- Noggin, 40, 47
- Noncoding RNAs, 91–92
- Nonmuscle myosin II heavy chain (NMMII), 196
- Notch1 pathway, 36
- Notch signaling, 193
- Novel phosphopeptide-capturing technology, 237–238
- NRON ncRNA, 91–92
- NSC cell populations, 175. *See also* Neural stem cells (NSCs)
- NSC-mediated repair, exogenous, 41
- NSC transplantation, 41
- N*-terminal labeling, 230
- Nuclear factor of activated T cells (NFAT), 91–92
- Nuclear transfer cloning, 196
- Nucleic acid libraries, 87–88
- Nucleic acids, amplified, 65
- NuGen proprietary amplification scheme, 65
- Null mice, *Gata4* and *Gata6*, 11
- Nurr1 transcription factor, 13
- Nurse cells, 30–31
- Oct3/4 homologues, 176
- Oct4-GFP reporter, 192
- Oct4 transcription factor, 83  
in ES cell fate determination, 9–10  
long-term expression of, 98
- Off-target activity, 94–95
- Oligodendrocytes, derivation of, 13
- Oligonucleotide sequences, 134
- Oligonucleotide spotting/synthesizing methods, 60
- Olomoucine, 116
- Oncogenesis, cellular changes related to, 49
- Oncogenic kinases, 131
- Oncogenic pathways, 48  
nurse cells and, 31
- Oncogenic targets, 51  
129 embryos, 3–4
- Optical encoding system, 117
- Orbitrap, 227
- Organ rejection, 37
- Organs, regeneration of, 207
- Orth, Anthony P., viii, 83
- Osteogenesis, modulation of, 194
- Osteosarcoma cells, 136
- Overexpressed cDNAs, profiling the function of, 88–90
- Overexpression  
of *Nanog*, 10  
of *Soes3*, 11

- Overexpression approach, versus RNAi-mediated approach, 95–96
- Overexpression experiments, false positives in, 94
- p38 inhibition, 195
- p38 inhibitors, 193
- p42/p44 MAP kinase inhibition, 133
- p53 function, genes critical for, 91
- p53 signaling, functional profiling of, 49
- Pancreatic  $\beta$  cells, proliferation of, 195
- Pancreatic cells, generation of, 15–16
- Pancreatic duodenal homeobox 1 (Pdx1), 15–16
- Paneth cells, 45–46
- Parabiosis experiments, 36
- Parallel synthesis methods, 110
- Parathyroid hormone (PTH), 36
- Parkinson's disease (PD), 40
- Pathologies, protein–protein interactions and, 125
- Pathway-building software packages, 68
- Pax4 transcription factor, 15
- PD098059 MEK inhibitor, 192
- PD168393 EDNRB inhibitor, 195
- Peptide mass mapping, 146
- Peptide mixtures, analysis by reverse-phase LC/MS/MS, 148
- Peptides
  - genes encoding, 224
  - ICAT-labeled, 232
  - important parameters of, 151
  - solid-phase synthesis of, 110
  - separation of, 147
- Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) agonists, 194
- Perturbation experiments, 182
- Petasis reaction, 115
- Peters, Eric C., viii, 145
- Peterson, Randall T., viii, 207
- Pharmacological approach, 109
- Pharmacotherapy
  - predicting patient response to, 73
  - realistic targets for, 71
- Phenotype-based approach, 190
  - screening method for, 191
- Phenylalanine hydroxylase (PAH) activity, 94
- 3-Phosphoinositide-dependent protein kinase (PDK1), 128
- Phosphatase inhibitors, 125–127
- Phosphatases, 93
- Phosphatidylinositol 3-kinase (PI3K), 235
- Phosphoinositide 3-kinase (PI3K), 15
- Phosphoinositide-3 kinase (PI3K), 6
- Phosphopeptide-capturing technology, novel, 237–238
- Phosphopeptides, enrichment of, 157
- Phosphorylation profile, 159
- Photocrosslinking, 128, 131
- Pianowski, Zbigniew, viii, 109
- Pkc1 identification, 135
- Planaria, in regeneration studies, 210
- Plaque screening, 60
- Plasmodium falciparum*, purine activity against, 117
- Platelet-derived growth factor (PDGF), 235
- PLK1 (polokinasase-1), 93
- Pluripotency
  - induction of, 200
  - measures of, 173–174
  - Oct4 and, 9–10
- Pluripotent ES cells, 4
- Pluripotent stem (iPS) cells, 2, 200
- Pluripotin, 8, 192, 198
- Polysialic acid form of neural cell adhesion molecule (PSA-NCAM), 39–40
- Posttranslational modifications (PTMs)
  - characterizing by mass spectrometry, 156–160
  - detection and localization of, 156
  - in proteomics, 157
- Precursor ion-scanning experiments, 158–159
- Precursors, 170
- Preimplantation blastocyst stage, 1
- Privileged scaffold, libraries based on, 118
- “Privileged structures,” 190–191
- Proapoptotic factors, 89–90
- Profiling assays, complex, 96
- Progenitor cancer pathway, 51
- Progenitor cells, 28
- Proliferation markers, 38–39
- Proof-of-concept study, 90, 92
- Protease profiling, 128, 130
- Protein(s)
  - enforced overexpression of, 90
  - mass spectrometric characterization of, 137–138, 145–167
  - tryptic digestion of, 156
- Protein expression levels, assessing changes in, 150
- Protein function, small-molecule modulators of, 217
- Protein identification, defined, 149
- Protein kinase A (PKA), 128
- Protein kinase inhibitors, 217
- Protein MS, 150. *See also* Mass spectrometry (MS); Protein quantitation
- Protein/peptide-capturing technologies, emerging, 236–238
- Protein phosphorylation, 237

- Protein–protein interactions  
 small-molecule antagonists of, 125  
 synthesis of libraries targeting, 126
- Protein quantitation, using mass spectrometry, 150–156
- Protein trafficking, 122
- Proteolytic activity, measuring differences in, 128
- Proteome, dynamic nature of, 153–156
- Proteomic research, mass spectrometry in, 224–230
- Proteomics  
 bottom-up, 159  
 posttranslational modifications in, 157  
 in stem cells, 223–242
- Proteomic strategies, 225  
 MS-based, 227, 229
- Proteomic technologies  
 advances in, 224  
 successful application of, 238
- Proteomic technology platforms, 225
- Proton transfer charge reduction, 160
- PTH/PTHrP receptor (PPR), 36
- PTH-related protein (PTHrP), 36
- PTP1B protein phosphatase, 125, 126
- Public gene expression datasets, 70–72
- PubMed citations, 84–85
- Purine-dependent enzymes, structure-based  
 libraries targeting, 115–118
- Purines, combinatorial libraries based on, 115–117
- Purmorphamine, transcriptome analysis of, 198
- Puromycin, 99
- Purvalanol B, 117
- Purvalanols, 132–133  
 targets of, 134
- QPCR (quantitative polymerase chain reaction), 70
- QS11 purine compound, 197, 198
- QTrap™ (hybrid linear ion trap-triple quadrupole)  
 mass spectrometers, 158
- Quadrupole ion trap (IT) analyzers, 226
- Quadrupole TOF (QTOF), 227
- Quantitative profiling studies, experimental  
 workflow for, 153, 154
- Quantitative proteomics, labeling methods  
 for, 232
- Quantitative proteomic scheme, 231
- Quantitative proteomics technologies, 230–232  
 alternative, 235
- Quantitative trait locus (QTL), 71
- Radicicol, 131
- Rao, Mahendra S., viii, 169
- RasGAP protein, 192
- Rate-limiting components, detecting, 94
- Reagent-targeting chemical functionality, 158
- Reddy, Venkateshwar A., viii, 145
- Reference standard, use of, 174, 175
- Regeneration, 195  
 approaches to, 208–210  
 candidate gene approaches to, 211–212  
 chemical screens for small molecules that affect,  
 217–218  
 choice of model organism for, 209, 210–211  
 complexity of, 208  
 complex pathways in, 219  
 efficiency of, 216  
 experimental approaches to, 211–218  
 molecular and cellular events  
 characterizing, 209  
 screens for differentially expressed genes  
 during, 212–215  
 screens for genetic and molecular enhancers of,  
 216–217  
 total set of genes required for, 216  
 versus wound response, 213–214
- Regeneration assays, 218
- “Regeneration-instructive” genes, 215–216
- Regeneration prevention mutations, genetic  
 screens for, 215–216
- Regeneration screens, 207–222
- Regeneration stages, markers of, 217
- Regeneration studies, 207
- Regenerative capabilities, drug stimulation  
 of, 188
- Regenerative cells, 208
- Regenerative medicine, 169
- Reporter genes, 217
- Research, proteomic, 224–230. *See also* Stem cell  
 research
- Resident intestinal stem cells (ISCs), 45
- Responder mESC line, 199
- Retinoic acid (RA) responsive genes, 214
- Retroviral insertion mutagenesis, 216
- Retroviral vectors, 96, 98
- Reverse genetics approaches, 216
- Reverse-phase HPLC (high performance liquid  
 chromatography), 147
- Reverse-phase LC/MS/MS, 148
- Reverse transcription-polymerase chain  
 reaction, 16
- Reverse-transfection approach, 88
- Reversine, 196, 198
- Rf tags, 110–112
- Rho GTPase, secramine and, 122
- Ribosomal assembly inhibition, 134, 135
- RNA, microarray analysis of, 218
- RNA expression, DNA microarrays for  
 measuring, 85

- RNAi-based genomic functional profiling, 90–91
- RNAi-based profiling experiments, false positives in, 94–95
- RNAi Consortium, The (TRC), 92
- RNAi libraries, development of, 198
- RNAi-mediated approach, versus overexpression approach, 95–96
- RNA interference (RNAi) libraries, genomic functional profiling using, 90–93
- RNA interference mechanisms, 87
- RNAi screens
- large-scale, 91
  - in planaria, 210
- RNA samples, partially degraded, 65
- Sachidanandan, Chetana, viii, 207
- Sample information software packages, 65–66
- Samples
- chemical modification of, 152
  - correlation ( $R^2$  score) among, 176
- Schofield, Robert, 29–30
- Schulze, Eric N., 1
- Screening strategies, designing better, 201
- Screens
- for anticancer compounds, 73
  - chemical, 217–218, 219
  - for differentially expressed genes, 212–215, 219
  - focused, 214
  - functional genomic, 198, 199–200, 209–210, 212–218
  - for genes differentially expressed during regeneration, 212–215
  - genomic overexpression, 136
  - high-throughput, 94, 112, 137, 198, 199–200, 218
  - in situ*, 112
  - osteogenesis and adipogenesis, 200–201
  - phenotype, 191, 193
  - plaque, 60
  - regeneration, 207–222
  - RNAi, 91, 210
  - small-molecule, 193
  - synthetic lethality, 134
- Sebaceous gland, 42
- Seramine, 122
- discovery of, 124
- Secreted proteins, identifying in conditioned media, 229
- Self-renewal, 171, 176, 187, 191–193, 223
- regulation of, 31–32
- Sengstaken, Crystal L., viii, 1
- Separation strategies, multidimensional, 149
- Sequencing protocols, 180
- Sequest™, 147, 224
- Serial transplantation, 28
- Serum/BMP, in mouse ES cell fate determination, 6–7
- Severe combined immunodeficient (SCID) mice, 36, 49
- SHDC activator, 88
- SHH (sonic hedgehog) transcription factor, 13
- Short-hairpin RNAs (shRNAs), 87. *See also* shRNA libraries
- virally encoded, 99
- Short tandem repeats (STRs), measures of, 173
- Short-term assays, 95
- Shotgun-based protein identification studies, 150
- “Shotgun” proteomics studies, 147
- Shp2 protein phosphatase, 125, 126
- shRNA libraries, 87, 91–92, 96, 99. *See also* Short-hairpin RNAs (shRNAs)
- Shumate, Deanna, viii, 83
- Signaling pathway protein components, identification of, 229–230
- Signaling pathways, 49
- developmental, 196–197
- Signal transducer and activator of transcription (STAT), 6
- “Silenced” region of chromosomes, detection of, 17
- Single-gene perturbation, 201
- Single nucleotide polymorphism analysis, 173
- Single-nucleotide polymorphisms (SNPs), identification of, 74
- siRNA libraries, 92–93. *See also* Small interfering RNAs (siRNAs)
- genome-scale, 93
- siRNA transfection protocols, 97, 98
- Skeletal diversification reactions, 115
- Skin cancers, 48
- Skin grafting, 44
- Skin stem cells, 42, 43, 45
- molecular markers of, 44
- Small interfering RNAs (siRNAs), 87. *See also* siRNA entries
- synthetic, 96
- Small-molecule antagonists, of protein–protein interactions, 125
- Small-molecule FXR agonists, 118
- Small-molecule inhibitors, 137, 197
- Small molecule libraries, 109, 137
- Small-molecule microarrays, 110, 128
- Small-molecule phenotypic screens, 193
- Small-molecule regulators, of stem cell fate, 191–197

- Small molecules, 188, 201  
 benefits of, 191  
 bioavailability of, 112  
 immobilizing, 128, 129  
 probing biology with, 109–144  
 target identification of, 198
- Smoothened (Smo), 194
- Socs3 cytokine signaling suppressor, ES cell  
 self-renewal and, 11
- Software, for microarray experiments, 66
- Solid-phase synthesis, of peptides, 110
- Solution-phase libraries, 125
- Somatic cell reprogramming, 196
- Somatic stem cells (SSCs), 29
- SOURCE database, 71
- Southern blots, 59
- Sox1 transcription factor, 13–14
- Sox2 transcription factor, 13–14  
 in ES cell fate determination, 10–11
- Species differences, in ES cells, 176
- Spectral counting techniques, 151
- Sperm progenitor cell, 31
- Spinal cord injury (SCI), 40
- Spinal insult, 40–41
- Spleen colony-forming units (CFU-S), 29
- “Split and mix” synthesis, 110
- “Split-pool” synthesis, 110, 117
- “Spontaneous” differentiation, 192
- Squamous layer, 42
- Stability, measures of, 173
- Stable isotope-labeling strategies/techniques,  
 151–152, 153
- Stable isotope labeling with amino acids in cell  
 culture (SILAC), 152, 155, 181, 230, 234–235
- Stat3 (signal transducer and activator of  
 transcription 3), 6, 136, 191
- Stat3/mouse ES cell lines, 8
- StemBase, 71
- Stem cell antigen1 (Scal)-positive cells, 34–36
- Stem cell biology  
 application of genomic functional profiling to,  
 97–99  
 convergence with proteomics, 238  
 genome-scale analysis of, 99  
 proteomic strategies for investigating, 225  
 quantitative proteomic technologies in, 230–232
- Stem Cell Database, 71
- Stem cell differentiation, 171
- Stem cell division, miRNA-mediated regulation  
 of, 180
- Stem cell engineering platforms, 182
- Stem cell fate, 188  
 small-molecule regulators of, 191–197
- Stem cell lineage relationships, 179
- Stem cell lines, global pairwise comparisons of,  
 177, 178
- Stem cell microarray experiments, data  
 repositories for, 71
- Stem cell mobilization, for medical applications,  
 33–34
- Stem cell populations  
 analysis of, 170  
 large-scale genomic analysis of, 169–186  
 methods used to characterize, 170  
 obtaining genomic and epigenetic data  
 from, 169
- Stem cell proliferation  
 dysregulation of, 32  
 injury as a regulator of, 43  
 self-renewal aspect of, 4
- Stem cell proteomic research, goal of, 227
- Stem cell regulation, 52–53  
 injury in, 43
- Stem cell research, 83, 201  
 chemical approaches to, 190–191  
 functional genomics approaches to, 198–200  
 SILAC technology in, 235
- Stem cells. *See also* Adult stem cell entries; Cancer  
 stem cell entries; Embryonic stem (ES) cells  
 (ESCs); Epithelial stem cell entries;  
 Hematopoietic stem cell entries; Human  
 embryonic stem cells (hESCs); Human MSCs;  
 Intestinal stem cell entries; Mesenchymal stem  
 cells (MSCs); Mouse embryonic stem cell  
 clones; Murine embryonic stem cells  
 (mESCs); Neural crest stem cells (NCSCs);  
 Neural stem cells (NSCs); Pluripotent stem  
 (iPS) cells; Resident intestinal stem cells  
 (ISCs); Subventricular zone stem cells;  
 Tissue-specific stem cell entries; Ventricular  
 zone stem cells  
 aging of, 177–179  
 allelic variability in, 177  
 biological background of, 188–190  
 cancer and, 49–51  
 categories of, 97  
 common traits in, 174–175  
 engineering, 182  
 expansion and differentiation of, 189–190  
 gathering information about, 181–182  
 improved molecular description of, 223  
 MS/MS for large-scale protein identification of,  
 227–228  
 mutations in, 52  
 novel methods to manipulate, 182  
 promise associated with, 169–170

- properties of, 174–181
- proteomics in, 223–242
- RNA levels in, 175
- self-renewal of, 191–193
- therapeutic potential of, 187
- tissue-specific, 196
- transducing, 98–99
- unique properties of, 224
- “Stemness,” defined 170–171, 176–177
- Stemness phenotype, lack of, 176–177
- Stem/progenitor cell fate, chemical compounds regulating, 189
- Stereochemical diversity, 115
- Streptozotocin (STZ)-induced diabetic mice, 15
- Stroke, ischemia from, 41
- Structure-based libraries, 115–118
- Study data, use of, 181–182
- Sub-genome-scale overexpression cDNA libraries, 96
- Subgenomic synthetic siRNA libraries, 93
- Subgranular zone (SGZ), 39
- Subgranular zone A (SGZ-A), 40
- Subgranular zone niche, 40
- Subproteome-capturing technologies, 236
- Substrates, affinity-labeled versions of, 158
- Subventricular zone (SVZ), 39
- Subventricular zone niche, 39–40
- Subventricular zone stem cells, 171
- “Supertransfection,” 200
- SVZ germinal area, 39
- SymAtlas, 71
- Symmetric division, 28, 193
- Synthesis, combinatorial, 110–112
- Synthetic lethality screens, 134
- Synthetic siRNAs, advantages of, 96
- T7-RNA polymerase, 65
- Tamoxifen analog library, 115
- Tandem mass spectrometry (MS/MS), 147, 225.
  - See also MS<sup>3</sup> (MS/MS/MS) strategies
  - coupled with immunopurification, 229–230
  - dominant neutral loss during, 159
  - for large-scale protein stem cell identification, 227–228
  - identification of secreted proteins using, 229
- Tandem mass tags, quantitation using, 155
- Tandem MS scans, 153
- Tandem TOF instruments (TOF-TOF), 227
- Tan group study, 69
- Tao, W. Andy, viii, 223
- Target-based approach, 190
- Target based kinase inhibitors, 192
- Targeted analyses, decision-driven, 147
- Target identification, 128–136
  - genomic approaches to, 135
  - selected molecules used for, 132
- Target/pathway identification, 198
- Teleost fish, in regeneration studies, 210–211
- Teratocarcinomas, 3
- Terminally differentiated cells, 51
- The Mouse Gene Prediction Database, 71
- Therapeutic applications, of hematopoietic stem cells, 37
- Therapeutic considerations
  - for cancer stem cells, 51–52
  - for epithelial stem cells, 44–45
  - for intestinal stem cells, 48
  - for neural stem cells, 40–41
- Therapeutics, identifying mechanism of action of, 73
- The RNAi Consortium (TRC), 92
- Thiol-containing reagents, 157
- Thiol-specific reagents, 233
- Three-dimensional organs, regeneration of, 208
- Thymidine marker, 38
- Tian, Qiang, viii, 223
- Time of flight (TOF) analyzers, 226–227
- “Tissue gene expression” databases, 70, 71
- Tissue maintenance, adult stem cells and, 27–28
- Tissue/organ-specific stem/progenitor cells, 195–196
- Tissue-specific stem cell populations, relationship to cancer stem cells, 179
- Tissue-specific stem cells, 171, 196
- Top-down approach, 227
- Top-down experiments, 159
- Totipotent blastomeres, 1–2
- TRAIL-induced apoptosis, 92–93
- Transcription factors, 175
- Transduction, tracking, 98
- Transfected cells, assays in, 96
- Transfection efficiencies, 96, 97
- Transforming growth factor  $\beta$  (TGF $\beta$ ) superfamily, 7
- Transit-amplifying (TA) cell, 44
- Transplantable growth matrices, 44
- TRC lentiviral shRNA library, 99
- Trichostatin A, 122
- Trichostatin A-inspired library, synthesis of, 123
- Triple-SILAC strategy, 152
- Tritiated thymidine, 38, 39
- Trophectoderm differentiation, 9
- Tubacin, 122
- Tubulin, 131
- $\alpha$ -Tubulin hyperacetylation, 122

- Tumor-initiating cell, 49  
Tumor suppressors, 91  
Tunicamycin, 134  
2DGE MALDI-TOF, 235  
Two-dimensional gel electrophoresis (2DGE),  
146, 150, 228  
Two-dimensional liquid chromatography  
(2DLC)-MS analysis, 236  
2D LC-MS/MS experiment, 149  
Two-hybrid method (Y2H), 133
- Ubiquitin, 158  
Ugi reaction, 114–115  
Unbiased genomic approaches, with unlabeled  
molecules, 134–136  
Unbiased libraries, 118–121  
Unique-clone array experiments, 94  
Universal stem cells, 170  
Unlabeled molecules, unbiased genomic  
approaches with, 134–136  
Ure2p-controlled genes, 121  
Uretupamine A, 121  
Uretupamine B, 121  
Uretupamines, discovery of, 118–121  
Urodele amphibians, in regeneration studies, 210
- Vascular endothelial growth factor (VEGF),  
40, 218  
Ventricular zone (VZ), 39  
Ventricular zone stem cells, 171  
VE-PTP protein phosphatase, 125, 126
- VHR protein phosphatase, 125, 126  
Viral libraries, 99  
Virally encoded RNAi libraries, 92  
Viral transduction, 182  
Viral tropispir, 96  
Viral vectors, 97  
Viral vector systems, 97–98  
Virtual dynamic library, 112
- Walker, John R., viii, 59  
Welch, Genevieve, viii, 83  
Whole organisms, for studying regeneration, 208  
“Whole-transcriptome” arrays, 63  
Williams three-component reaction, 115  
Winssinger, Nicolas, viii, 109  
Wnt/ $\beta$ -catenin pathway, 192, 230  
Wnt pathway, 47, 197  
Wnt signaling, functional profiling of, 89  
World Drug Index, 112  
Wound response, versus regeneration, 213–214
- Xanthosine (Xs), 193  
*Xenopus laevis*, in regeneration studies, 213  
Xu, Yue, ix, 187
- Yeast three-hybrid (Y3H), 133–134  
Ying, Qi-Long, ix, 1
- Zebrafish, in regeneration studies, 210–211, 212,  
213, 215, 218  
Zhang, Jia, ix, 83